Compare PPSI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | NSRX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 38.9M |
| IPO Year | 2008 | 2024 |
| Metric | PPSI | NSRX |
|---|---|---|
| Price | $2.89 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 96.1K | 10.2K |
| Earning Date | 04-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,627,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $2.35 | $1.98 |
| 52 Week High | $6.29 | $9.50 |
| Indicator | PPSI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 52.07 |
| Support Level | $2.73 | $2.90 |
| Resistance Level | $3.17 | $4.49 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 49.22 | 61.05 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets. The Company launched two new product platforms namely, PRYMUS, a new, mobile on-site power system concentrating on customers with requirements of 1-10 megawatts of mobile power and PowerCore, a residential and small commercial based primary generator system integrating a DC fast charger into one solution.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.